


Claims:

Claims 1-14 (**canceled**)

15. (**currently amended**) A polypharmacophore represented by formula (II):



(II)

wherein:

R₁ is -CO₂R₄[[,]] or -CO₂N(R₄)₂, ~~aryl, alkyl, aralkyl, or aralkenyl;~~

R₂ represents independently for each occurrence H, F, Cl, Br, or I, ~~amino, azido, nitro, sulfonate, sulfonyl, cyano, hydroxyl, alkyl, aryl, heteroalkyl, heteroaryl, aralkyl, trialkylsilyl, or acyl;~~

R₃ represents independently for each occurrence H, F, Cl, Br, or I, ~~amino, azido, nitro, sulfonate, sulfonyl, cyano, hydroxyl, alkyl, aryl, heteroalkyl, heteroaryl, aralkyl, trialkylsilyl, or acyl;~~

R₄ represents independently for each occurrence H[[,]] or alkyl, ~~aryl, alkenyl, alkynyl, heteroalkyl, or heteroaryl;~~ and

the stereochemical configuration of the carbon-carbon double bond is Z, E, or a mixture of Z and E.

16. (**canceled**)

17. (**canceled**)

18. (**currently amended**) ~~The polypharmacophore of claim 15, wherein said polypharmacophore is used to modulate~~ A method of modulating the function of the dopaminergic system in a mammal, comprising the step of:

administering to a mammal in need thereof a therapeutically effective amount of a polypharmacophore of claim 15.

19. **(currently amended)** ~~The polypharmacophore of claim 15, wherein said polypharmacophore is used to treat diseases and conditions~~ A method of treating a disease or condition selected from the group consisting of Alzheimer's Disease, Huntington's Disease, depression, attention deficit disorder, autism, obesity and inflammation in a mammal; comprising the step of:

administering to a mammal in need thereof a therapeutically effective amount of a polypharmacophore of claim 15.

Claims 20-54 **(canceled)**


55. **(previously presented)** The polypharmacophore of claim 15, wherein R_2 is F.

56. **(previously presented)** The polypharmacophore of claim 15, wherein R_2 is F and R_3 is H.

57. **(previously presented)** The polypharmacophore of claim 15, wherein R_1 is CO_2R_4 .

58. **(previously presented)** The polypharmacophore of claim 15, wherein R_1 is CO_2R_4 and R_4 is H.

59. **(previously presented)** The polypharmacophore of claim 15, wherein said compound is selected from group consisting of:



60. **(previously presented)** A pharmaceutical composition, comprising:

a polypharmacophore of claim 15, 55, 56, 57, 58 or 59, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier.